We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Australia's adult stem cell company, Mesoblast, has announced that it had signed
an agreement for production of specialized adult stem cells, known as Mesenchymal
Precursor Cells (MPCs), to be used in human pilot clinical trials in patients
with orthopedic and cardiovascular diseases.
Cellular Genomics (CGI), a chemical genetics based drug discovery and development
company, has announced the completion of a key performance milestone in its
joint kinase discovery program with Serono.
Seattle Genetics has announced that CuraGen has exercised
its option to designate a second antigen target under the parties' existing
antibody-drug conjugate (ADC) collaboration, triggering a $1 million payment
to Seattle Genetics.
Barr Laboratories has filed a lawsuit against the FDA in federal court to obtain
180 days of marketing exclusivity for its generic version of Aventis' Allegra-D
allergy drug.
More light may soon shine on the financial deals made between
drugmakers and pharmaceutical benefit managers (PBMs), as Maine moves closer
to implementing its PBM disclosure law.
GlaxoSmithKline (GSK) was recently hit with an FDA warning letter for presenting
a misleading promotional panel for its cardiovascular drug Coreg at an industry
conference last June.
Voyager Pharmaceutical, the biopharmaceutical company focused on diseases of
aging and development, has announced the receipt of commitments for a $16 million
private financing.
Glenmark Laboratories has sold 16 percent of its equity in the company through
a private placement to UK-based Springhill Bioventure Fund and UTI Venture Fund
for a consideration of around $5 million.
Pharmaceutical services giant Cardinal Health is floating plans to build a biotech
manufacturing facility in Raleigh, N.C., that could cost as much as $500 million
and create 1,500 jobs over 10 years.